SG194511A1 - Preparation of high-purity gadobutrol - Google Patents

Preparation of high-purity gadobutrol Download PDF

Info

Publication number
SG194511A1
SG194511A1 SG2013077094A SG2013077094A SG194511A1 SG 194511 A1 SG194511 A1 SG 194511A1 SG 2013077094 A SG2013077094 A SG 2013077094A SG 2013077094 A SG2013077094 A SG 2013077094A SG 194511 A1 SG194511 A1 SG 194511A1
Authority
SG
Singapore
Prior art keywords
gadobutrol
water
solution
purity
ion exchanger
Prior art date
Application number
SG2013077094A
Other languages
English (en)
Inventor
Johannes Platzek
Wilhelm Trentmann
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46208435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG194511(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of SG194511A1 publication Critical patent/SG194511A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2013077094A 2011-04-21 2012-04-17 Preparation of high-purity gadobutrol SG194511A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011100128 2011-04-21
PCT/EP2012/057013 WO2012143355A1 (fr) 2011-04-21 2012-04-17 Préparation de gadobutrol de pureté élevée

Publications (1)

Publication Number Publication Date
SG194511A1 true SG194511A1 (en) 2013-12-30

Family

ID=46208435

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013077094A SG194511A1 (en) 2011-04-21 2012-04-17 Preparation of high-purity gadobutrol

Country Status (34)

Country Link
US (2) US10072027B2 (fr)
EP (2) EP2896405B1 (fr)
JP (3) JP6096757B2 (fr)
KR (3) KR20190079682A (fr)
CN (1) CN103547573B (fr)
AR (1) AR086190A1 (fr)
AU (2) AU2012244791B2 (fr)
BR (1) BR112013027028B1 (fr)
CA (1) CA2833659C (fr)
CL (1) CL2013003045A1 (fr)
CO (1) CO6801752A2 (fr)
CU (2) CU24439B1 (fr)
DK (1) DK2896405T3 (fr)
DO (1) DOP2013000245A (fr)
EA (2) EA201600272A1 (fr)
EC (1) ECSP13013010A (fr)
ES (1) ES2780599T3 (fr)
GT (1) GT201300253A (fr)
HR (1) HRP20200336T1 (fr)
IL (1) IL228885A (fr)
LT (1) LT2896405T (fr)
MX (1) MX362133B (fr)
MY (1) MY163709A (fr)
NZ (1) NZ616637A (fr)
PE (1) PE20141325A1 (fr)
PH (1) PH12013502168B1 (fr)
PL (1) PL2896405T3 (fr)
PT (1) PT2896405T (fr)
RS (1) RS60001B1 (fr)
SG (1) SG194511A1 (fr)
SI (1) SI2896405T1 (fr)
TW (1) TW201249818A (fr)
WO (1) WO2012143355A1 (fr)
ZA (1) ZA201308706B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2896405B1 (fr) * 2011-04-21 2020-02-19 Bayer Intellectual Property GmbH Préparation de gadobutrol de grande pureté
EP3102566B1 (fr) * 2014-02-06 2018-09-12 T2Pharma GmbH Procédé de purification de l'acide 1,4,7,10-tétraazacyclododécane-1,4,7,10-tétraacétique
KR101693400B1 (ko) * 2014-09-17 2017-01-05 에스티팜 주식회사 칼코부트롤의 제조방법
KR101646211B1 (ko) * 2014-11-12 2016-08-05 (주)디아이테크 자기공명영상용 조영제의 제조방법
KR101653064B1 (ko) * 2014-12-26 2016-09-09 에스티팜 주식회사 가도부트롤의 제조방법
EP3101012A1 (fr) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique
HRP20200922T1 (hr) 2016-09-27 2020-09-18 Bayer Pharma Aktiengesellschaft Postupak za proizvodnju kristalnog oblika modifikacije a kalkobutrola
CN106543094A (zh) * 2016-11-04 2017-03-29 嘉实（湖南）医药科技有限公司 高纯度钆布醇的制备方法
ES2814555T3 (es) 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
GB201703227D0 (en) * 2017-01-20 2017-04-12 Ge Healthcare As Plastic containers
CN109293592A (zh) * 2017-07-24 2019-02-01 天津科伦药物研究有限公司 一种制备钆布醇的方法
KR101971435B1 (ko) * 2017-08-29 2019-04-24 주식회사 엔지켐생명과학 가도부트롤 중간체 및 이를 이용한 가도부트롤의 제조 방법
CN108840832A (zh) * 2018-06-29 2018-11-20 广州康瑞泰药业有限公司 一种钆布醇中间体的制备方法
US12227527B2 (en) 2018-07-10 2025-02-18 Biophore India Pharmaceuticals Pvt. Ltd Process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes
KR102167614B1 (ko) 2018-08-23 2020-10-19 에스티팜 주식회사 가도부트롤의 제조방법
KR102934987B1 (ko) * 2018-11-23 2026-03-09 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
KR20210102371A (ko) 2018-12-12 2021-08-19 메디비콘 아이엔씨. 지속적 신장 대체 요법에서 경피 사구체 여과율 측정의 용도
GB201919073D0 (en) * 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
CN113087680A (zh) * 2020-01-08 2021-07-09 威智医药有限公司 Dota晶型及其制备方法
CN113105407A (zh) * 2020-01-13 2021-07-13 北京北陆药业股份有限公司 一种钆布醇新型晶型及其制备方法
KR20210114742A (ko) * 2020-03-11 2021-09-24 주식회사 엔지켐생명과학 칼테리돌의 제조방법
CN114539178B (zh) * 2020-11-26 2024-03-15 江苏恒瑞医药股份有限公司 一种钆布醇的纯化方法
CN114573522A (zh) * 2020-11-30 2022-06-03 江苏恒瑞医药股份有限公司 一种考布曲钙的新晶型及其制备方法
WO2022165424A1 (fr) * 2021-02-01 2022-08-04 Inventure, LLC Procédés de synthèse et compositions d'agents de contraste intermédiaires faibles et d'agents de contraste intermédiaires dichélates faibles
CN112939806B (zh) * 2021-03-08 2023-05-16 山东新华制药股份有限公司 一种卡比多巴的精制方法
CN113527223B (zh) * 2021-06-22 2023-05-09 安徽普利药业有限公司 一种钆布醇的精制方法
CN114105897B (zh) * 2021-07-29 2023-04-04 安徽普利药业有限公司 一种钆特醇的制备方法
CN116023345A (zh) * 2023-02-16 2023-04-28 渭南瑞联制药有限责任公司 一种钆布醇中间体杂质的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
NL194579C (nl) 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3625417C2 (de) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
DE4035760A1 (de) 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4140779A1 (de) 1991-12-06 1993-06-09 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Verfahren zur herstellung von mono-n-substituierten tetraazamakrocyclen
US5410043A (en) 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
DE4237943C2 (de) 1992-11-06 1997-10-23 Schering Ag Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate
DE4218744C2 (de) 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
IT1275426B (it) 1995-05-16 1997-08-07 Bracco Spa Recupero del gadolinio e dei suoi agenti complessanti da soluzioni acquose contenenti i loro complessi
DE19608307C1 (de) 1996-02-26 1997-08-28 Schering Ag Verfahren zur Herstellung von 1,4,7,10-Tetraazacyclododecan und dessen Derivaten
US5744616A (en) 1996-02-26 1998-04-28 Schering Aktiengesellschaft Process for the production of 1,4,7,10-tetraazacyclododecane and its derivatives
DE19724186C2 (de) 1997-06-02 2002-07-18 Schering Ag Verfahren zur Mono- und 1,7-Bis-N-ß-Hydroxyalkylierung von Cyclen und die entsprechenden N-ß-Hydroxyalkyl-1,4,7,10-tetraazacyclododecan-Li-Salz-Komplexe
IT1292128B1 (it) * 1997-06-11 1999-01-25 Bracco Spa Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici
IT1292127B1 (it) 1997-06-11 1999-01-25 Bracco Spa Processo per la dissalazione di sostanze instabili a ph acidi
ATE226520T1 (de) 1998-09-08 2002-11-15 Kba Giori Sa Sicherheitsdruckmaschine für wertpapiere
DE10064467C2 (de) 2000-12-15 2002-10-31 Schering Ag Lithium-Komplexe von N-(1-Hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecan, deren Herstellung und Verwendung
DE102009053171B4 (de) 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
WO2011054480A1 (fr) 2009-11-09 2011-05-12 Bayer Schering Pharma Aktiengesellschaft Préparation de gadobutrol au moyen d'une membrane céramique
DE102010013833A1 (de) 2010-03-29 2011-09-29 Bayer Schering Pharma Aktiengesellschaft Herstellung von Gadobutrol mittels Dimethylformamiddimethylacetal
DE102010023105A1 (de) 2010-06-04 2011-12-08 Bayer Schering Pharma Aktiengesellschaft Gadobutrolherstellung im Eintopfverfahren mittels DMF-acetal und N-Methylimidazol
EP2896405B1 (fr) * 2011-04-21 2020-02-19 Bayer Intellectual Property GmbH Préparation de gadobutrol de grande pureté
KR101653064B1 (ko) 2014-12-26 2016-09-09 에스티팜 주식회사 가도부트롤의 제조방법

Also Published As

Publication number Publication date
US10435417B2 (en) 2019-10-08
MX2013012290A (es) 2013-11-21
EP2896405A1 (fr) 2015-07-22
ZA201308706B (en) 2015-08-26
US10072027B2 (en) 2018-09-11
PH12013502168A1 (en) 2014-01-13
MX362133B (es) 2019-01-07
JP2018188477A (ja) 2018-11-29
KR20200059319A (ko) 2020-05-28
JP2017031220A (ja) 2017-02-09
PH12013502168B1 (en) 2019-11-27
CN103547573B (zh) 2016-08-17
BR112013027028A2 (pt) 2016-12-27
CU20160163A7 (es) 2017-02-02
KR20190079682A (ko) 2019-07-05
NZ616637A (en) 2016-01-29
US20180105537A1 (en) 2018-04-19
AU2012244791B2 (en) 2017-04-27
RS60001B1 (sr) 2020-04-30
SI2896405T1 (sl) 2020-04-30
KR102003570B1 (ko) 2019-07-24
CA2833659C (fr) 2019-12-03
EP2699556A1 (fr) 2014-02-26
IL228885A (en) 2016-11-30
CU20130142A7 (es) 2014-02-28
EA026572B1 (ru) 2017-04-28
HK1193817A1 (zh) 2014-10-03
CO6801752A2 (es) 2013-11-29
EA201600272A1 (ru) 2016-12-30
CA2833659A1 (fr) 2012-10-26
CL2013003045A1 (es) 2014-05-02
MY163709A (en) 2017-10-13
EA201301182A1 (ru) 2014-08-29
AU2012244791A1 (en) 2013-10-31
EP2896405B1 (fr) 2020-02-19
WO2012143355A1 (fr) 2012-10-26
LT2896405T (lt) 2020-03-25
ECSP13013010A (es) 2013-12-31
HRP20200336T1 (hr) 2020-06-12
JP2014522387A (ja) 2014-09-04
PE20141325A1 (es) 2014-10-08
TW201249818A (en) 2012-12-16
JP6096757B2 (ja) 2017-03-15
ES2780599T3 (es) 2020-08-26
GT201300253A (es) 2015-01-16
DK2896405T3 (da) 2020-04-06
AR086190A1 (es) 2013-11-27
IL228885A0 (en) 2013-12-31
KR20140035911A (ko) 2014-03-24
AU2017204495A1 (en) 2017-07-20
US20140107325A1 (en) 2014-04-17
CN103547573A (zh) 2014-01-29
DOP2013000245A (es) 2013-12-31
CU24439B1 (es) 2019-09-04
PT2896405T (pt) 2020-03-31
BR112013027028B1 (pt) 2020-08-11
PL2896405T3 (pl) 2020-06-15

Similar Documents

Publication Publication Date Title
AU2012244791B2 (en) Preparation of high-purity gadobutrol
EP4151637B1 (fr) Agents de contraste à base de pcta contenant du gadolinium
TW201245189A (en) Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
Chatterton et al. The effect of pyridinecarboxylate chelating groups on the stability and electronic relaxation of gadolinium complexes
Li et al. A gadolinium (III) complex with 8-amidequinoline based ligand as copper (II) ion responsive contrast agent
IL246754A (en) Method for Making 5-Hydroxy Crystal-H1-Imidazole-4-Carboxamide 4/3 Hydrate
Kong et al. Naphthyridine-based lanthanide complexes worked as magnetic resonance imaging contrast for guanosine 5′-monophosphate in vivo
US10100055B2 (en) Imidazopyrroloquinoline salt, method for producing the same, medicament, cosmetic, and food
Sengar et al. Syntheses and crystal structures of gadolinium and europium complexes of AAZTA analogues
HK1193817B (en) Preparation of high-purity gadobutrol
HK40115608A (en) Gadolinium bearing pcta-based contrast agents
HK1229336B (en) Pharmaceutical process and intermediates